Abstract: The invention concerns a method for relieving idiopathic ocular pain by administering an effective amount of a fluid composition comprising hyaluronic acid, a hyaluronic acid analogue, or a combination thereof, to the eye of a human or non-human animal subject, wherein the fluid composition is administered after onset of the idiopathic ocular pain and in the absence of detectable signs known to cause ocular pain.

Abstract: The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.

Abstract: The present invention relates to a yeast-derived polysaccharide inducing Treg cells and a use thereof and, more particularly, to a polysaccharide comprising mannan and ?-glucan, an composition for immunomodulation comprising the polysaccharide as an active ingredient, a pharmaceutical composition or food comprising the polysaccharide as an active ingredient for prevention or treatment of immune disease or inflammatory disease, a method for preparation of regulatory T cells by using the polysaccharide, a cell therapeutic agent comprising the regulatory T cells prepared by the preparation method as an active ingredient, and a treatment method using same.

Abstract: A method of treating and/or preventing viral infections caused by common cold, influenza, and coronaviruses with or without symptoms is based on a fact that virus's survival time depends on the temperature and relative humidity, and an assumption based on scientific tests that a virus can be inactivated/killed or its ability to penetrate and replicate copies inside living cells can be weakened in high temperature environment by heat exposure to the virus. Creating high temperature environment in the upper respiratory and gastrointestinal (GI) tracts and preventing spread of the virus into the lower part of the respiratory tract using continuous and prolonged hot water exposure on the virus prevents development of pneumonia and expedite recovery.

Abstract: The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.

Abstract: Provided herein are formulations for the safe and effective topical delivery of buffering agents. The invention includes formulations and methods to balance electrolytes, overcome cation overload, and/or deliver buffers with and without counterions that can be combined in a single use formulation or alternatively in separately applied formulations. Also provided are methods of using the formulations for the treatment of a wide variety of disorders relating to electrolyte imbalance, cation overload, or related conditions.

Abstract: A therapeutic composition for treatment of coronavirus infections. The therapeutic composition contains a gold compound effective for Rheumatoid Arthritis treatment that both generates gold-S bonds at the active pockets of the main protease of the virus and suppresses the virus induced inflammations in the body.

Abstract: The present invention relates to a method of treating disorders caused by iron deficiency, comprising administering to a subject in need thereof a therapeutically effective amount of a formulation comprising, as active ingredients, a composition comprising at least 40% of 5?-ribonucleotides by weight of the total weight of the composition, and an inorganic iron salt.

Abstract: The use of a preparation for nutrition-based support of the body's own wound healing processes at the local and systemic level by oral intake of the preparation, which contains per gram as a basic preparation the following mixture of vitamins and nutrients: a. 330-385 ?g of vitamin B1, b. 420-490 ?g of vitamin B2, c. 4.8-5.6 mg of vitamin B3, d. 1.8-2.1 mg of vitamin B5, e. 420-490 ?g of vitamin B6, f. 15-18 ?g of vitamin H, g. 80-390 ?g of vitamin B9, h. 1.0-4.9 ?g of vitamin B12, i. 32-156 mg of vitamin C, j. 150-731 mg of magnesium, k. 4-20 mg of zinc and l. 3-200 mg of tryptophan.

Abstract: A composition to treat epidermal insults may have an ungraphenated detonation synthesis nanodiamonds (UDSND) and medical grade Siberian Sea Buckthorn Berry Oil (SBB) composition in a blended uniform composition with 1% hydrocortisone cream; wherein the UDSND are at 2 nm to 4 nm in initial crystal size and in the range of 0.2% to 0.5% of the UDSND-SBB composition weight and the SBB which is 99.5% to 99.8% of the UDSND-SBB composition weight; and wherein total composition ratio is in the range of about 3:1 to 10:1 hydrocortisone cream to UDSND-SBB composition. Preferably, the total composition ratio can be about 6:1 hydrocortisone cream to UDSND-SBB composition.

Abstract: Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers.

Abstract: The invention provides systems and methods for determining and predicting the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a condition associated with an entity, for example the effect of providing a population of tumor infiltrating lymphocytes (TILs) on a subject having cancer. The systems and methods rely on acquiring a computer readable analytical signature from a sample of the entity, obtaining a trained model output value for the entity by inputting the computer readable analytical signature into a tier trained model panel, and classifying the entity based upon the trained model output value with a time-to-event class in an enumerated set of time-to-event classes, each of whom is associated with a different effect of providing a population of TILs to the entity.

Abstract: The present disclosure is directed towards genetically engineered TCR-T cells to recognize tumor antigens and simultaneously secrete a binding protein that blocks an immune checkpoint molecule and TGF-beta. These engineered T cells demonstrate stronger antitumor response and reduced T cell exhaustion. The present disclosure provides immunotherapy against HPV- or EBV-positive cancers, among others.

Abstract: A therapeutic composition is provided. The therapeutic composition is particularly useful in the treatment of various symptoms arising from immune responses to pathogenic infections. The therapeutic compositions includes an acellular mammalian birth tissue material composition and a stem cell composition. Methods of treatment are also provided.

Abstract: A method for using Cold Atmospheric Plasma based T cell therapy for treating cancer including treating tumor cells with cold atmospheric plasma to permeabilize the tumor cells, condensing a mammalian CRISPR plasmid vector into compact nanostructures using one of poly-L-lysine (PLL) and Star-shaped poly(ethylene glycol)-block-polyethylenimine, and transferring into the tumor cells catalytically inactive Cas9 (dCas9) containing transcriptional activators (VP64-p65-Rta) paired with single guide RNAs (sgRNAs) and plasmid DNA (CRISPRa system) to elicit immune responses by enhancing the presentation of tumor-associated antigens.

Abstract: The present disclosure provides compositions and methods for engineered cellular compositions and methods of immunotherapy utilizing the same. Compositions of the present disclosure for immune cell regulation comprise a chimeric antigen receptor polypeptide, a T cell receptor polypeptide, and combinations thereof.

Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

Abstract: The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARs), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties.

Abstract: The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.

Abstract: Ultrasound-guided rete testis injection/aspiration devices and methods are described. Some methods include inserting a needle into the rete testis space of a patient and injecting a therapeutic medium through the needle into the rete testis space and seminiferous tubules of the testis. The therapeutic medium can help to treat infertility. In some examples, the method can include monitoring intra-testicular pressure of the patient. In some examples, the therapeutic medium can include stem cells. In some examples, the therapeutic medium can include gene therapy vectors. In some examples, the method can include flushing the rete testis space and seminiferous tubules with a saline solution through the needle. Exemplary devices can include a dual lumen needle, a collection tube, a dual function pump, and flexible tubing. The dual function pump can include a dual syringe pump and a vacuum pump.

Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Abstract: A cell preparation for treating brain tumors used in combination with a prodrug that is converted to 5-fluorouracil by cytosine deaminase, wherein the cell preparation comprises neural stem cells derived from pluripotent stem cells having a cytosine deaminase gene and a uracil phosphoribosyltransferase gene is provided to establish new means for treating brain tumors.

Abstract: Provided are fetal tissue cells or a fetal tissue extract which can effectively prevent or treat bone disorders or diseases.

Abstract: Disclosed are compositions and methods related to the use of adipocytes for sustained release of anti-cancer therapeutics and treatment of cancer. In one aspect, disclosed herein are engineered adipocytes comprising an anti-cancer prodrug (such as, for example, doxorubicin prodrug) and a conjugated fatty acid (such as, for example, one or more isomers of conjugated linoleic acid including, but not limited, to 9cis, 11trans, 10trans, and/or 12cis).

Abstract: The present invention relates to an in vitro method for preparing and producing canine pancreatic islets from immature pancreatic tissue. Such islets express, produce and secrete insulin upon glucose stimulation. The invention further encompasses canine pancreatic islets obtainable according to the present method, islet population of said islets and compositions comprising said islets. It also relates to transduced canine pancreatic islets, or tumours or cells derived thereof. The present invention also concerns the use of said canine pancreatic islets or cells derived thereof for treating a canine pancreatic disorder, such as canine diabetes, or for diagnosing canine diabetes.

Abstract: The present invention relates to a process for isolating Small Extracellular Vesicles secreted by umbilical cord blood mononuclear cells (UCBMNCs) and compositions comprising said Small Extracellular Vesicles, which are useful to be applied to autoimmune diseases therapeutics or prophylactics and/or cosmetic purposes. The proposed process for isolating UCBMNCs Small Extracellular Vesicles comprises three main steps: i) a first step of sequential centrifugation, ii) a second step of microfiltration combined with ultrafiltration (UF), and iii) a third step of size exclusion chromatography (SEC) and aims to achieve highly pure Small Extracellular Vesicles and in a higher yield. The SEVs compositions comprise specific type of proteins, RNA and lipids, that enables them to be very effective when applied to inflammatory and autoimmune diseases therapeutics, such as psoriasis, lupus, atopic dermatitis, eczema, etc. and also to cosmetic or prophylactic compositions.

Abstract: This document provides methods and materials for identifying and treating mammals responsive to obesity treatments. For example, methods and materials for assessing a mammal's gut microbiota (e.g., a human's gut microbiota) to identify that mammal (e.g., human) as being responsive to an obesity treatment are provided. Methods and materials for treating obesity by assessing a mammal's gut microbiota (e.g., a human's gut microbiota) to identify that mammal (e.g., human) as being responsive to an obesity treatment and proceeding with an obesity treatment also are provided.

Abstract: The present disclosure relates to a method for treating or preventing a viral and/or bacterial respiratory infection in a subject, the method comprising administering to the respiratory tract of the subject an effective amount of one or more bacteria from family Pasteurellaceae.

Abstract: The present disclosure provides immunomodulatory compositions comprising live Caulobacter crescentus (CC). Immunomodulatory compositions of the present disclosure are useful for modulating an immune response in an individual. The present disclosure thus provides methods of modulating an immune response in an individual, involving administering an immunomodulatory composition comprising live CC to the individual.

Abstract: The present invention relates to the strain Phascolarctobacterium faecium DSM 32890 and to its use for the regulation of appetite and the treatment and/or prevention of overweight or the associated metabolic and immunological changes, specifically, hyperglycaemia, glucose intolerance, insulin resistance, dyslipidemia (hypertriglyceridemia, hypercholesterolemia), metabolic syndrome, diabetes and intestinal and/or peripheral tissue inflammation.

Abstract: A probiotic formulation is provided including one or more bacteria, bacterial strains or bacterial species of the genus Veillonella, genus Faecalibacterium, genus Phascolarctobacteria, genus Oscillospira, genus Ruminococcus, genus Bacteroides, genus Blautia, family Christensenellaceae, genus Dialister, or phylum cyanobacteria.

Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.

Abstract: A method of improving microbiome within an animal can comprise administering to the animal a composition comprising a probiotic and psyllium, wherein the probiotic comprises at least one of any suitable strain or subspecies of Enterococcus. Compositions containing a probiotic and psyllium are also provided herein.

Abstract: The present invention relates to the treatment of bacterial infections and the reduction of inflammatory response using bacteriophage compositions.

Abstract: The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages that target oncogenic (tumorigenic) bacteria, and use of the same for treating or preventing cancer.

Abstract: A nasal composition comprising one or more vegetable oils that possess medicinal properties for the treatment or improvement of brain/central nervous system conditions and diseases; phospholipids and optionally glycol, the composition being cannabinoids-free.

Abstract: A method for producing a powderized cannabis oil includes providing a cannabis oil; dissolving the cannabis oil in an alcohol to form a solution; mixing amylose, amylopectin, or a combination thereof into the solution; and evaporating the alcohol.

Abstract: The present disclosure relates to compositions and methods for treating a subject having a COVID-19 infection. The present disclosure relates to the use of Dichrostachys glomerata extract as a medicament for the treatment of COVID-19 infections.

Abstract: Disclosed are various embodiments of natural plant compositions. Particularly, the natural plant compositions may consist of plant chemicals, such as terpenes and cannabinoids, natural oils such as hemp seed oil and essential oils such as peppermint oil and lemon oil. Delivery methods for administration of the compositions include topical administration, an oral administration and a pulmonary administration. The compositions are used for a variety of reasons ranging from medicinal to recreational.

Abstract: The present disclosure relates to a composition comprising a Salvia miltiorrhiza Bunge extract as an active ingredient for treatment or prevention of benign prostatic hyperplasia or alopecia, the Salvia miltiorrhiza Bunge extract being characterized by containing tanshinones in 2-70%, including tanshinone1, tanshinone2a, cryptotanshinone, and dihydrotanshinone, and can provide a pharmaceutical composition and a health functional food for treatment or prevention of alopecia and benign prostatic hyperplasia.

Abstract: The invention provides to an enriched Withania somnifera (Ashwagandha) extract composition comprising withanolide glycosides, withanolide aglycones and reduced levels of withaferin-A. The invention also provides to process for the preparation of these compositions and further provides to methods of improving testosterone levels, energy levels, sustained energy, vigor, stamina, and muscle mass and muscle strength using these compositions.

Abstract: The application provides nutraceutical compositions supporting an active life style and helps with the post-exercise recover. In one embodiment, the nutraceutical composition includes a gelling component in a sufficient amount to provide a cohesive gelled product and an active component. The active component consists of a vitamin B composition, a carbohydrate composition, an amino acid composition, an antioxidant composition, and an anti-inflammatory.

Abstract: This invention pertains to an herbal paste comprising a mixture comprising 15 to 25 parts by weight ginger root, 15 to 25 parts by weight turmeric root, 15 to 25 parts by weight garlic 15 to 25 parts by weight lime fruit, 15 to 25 parts by weight lemon fruit, 0.5 to 1.5 parts by weight bitter kola nut, 15 to 25 parts by weight natural honey and B. optionally up to 50 parts water per 100 parts of Mixture A. Also claimed is a drink from the herbal mixture and a method of using the herbal mixture for active inhalation.

Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.

Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG; purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

Abstract: The present invention relates to the field of (bio-)medicine, and more particularly to the treatment of copper-related diseases. Novel means and methods for depleting (excess) copper from organs and/or the circulation are provided. Agents with a high copper binding affinity and stabilized forms thereof are provided, as well as a novel treatment regimen. The means and methods of the present invention are particularly useful for treatment of Wilson Disease, but also for treatment of other conditions.

Abstract: Described herein are cell-selective mRNA constructs that can contain a RNA of interest and one or more miRNA targets. The cell-selective mRNA constructs described herein can be used to express an RNA of interest to a cell in a cell-selective manner.

Abstract: This disclosure provides for the application of a multi-disciplinary analysis of information sources to draw novel conclusions that result in new methods to diagnose, prevent or treat COVID-19. COVID-19 appears to be an extremely complex disease, encompassing three critical aspects at least: a viral infection, an immune system disorder, and a cardiovascular/pulmonary/renal disease with significant coagulation system dysregulation. This disclosure principally focuses on modes and sites of infection of the SARS COV-2 virus and the role of lectins, the lectin complement pathway, coagulation system dysfunction, related genetic polymorphisms, trypsin-like serine proteases, interferon stimulation of the innate immune system, and other factors in the disease process. Corresponding methods to address the COVID-19 pandemic are provided.

Abstract: Osteoinductive, bone morphogenic protein receptor-binding peptides are disclosed. The peptides may be used to coat or infuse scaffolds for use as implants into bone for enhancing the growth, proliferation, and differentiation of mesenchymal stem cells and/or osteoblasts in the bone.

Abstract: The present invention provides for a dosing schedule for the intratumoral delivery of an immunostimulatory cytokine in combination with systemic delivery of a checkpoint inhibitor. In particular, it provides delivery of a plasmid encoding the immunostimulatory cytokine, e.g., IL-12, using intratumoral electroporation, and the systemic delivery of a PD-1 antagonist.